Therefore, investigating the impact of long-term rapamycin treatment on insulin BBB transport, especially in mouse models of Alzheimer’s disease, still warrants further investigation as a mechanism for contributing to the cognitive improvements due to rapamycin. The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.